PolyPid

Investors deck

February 2026

Forward Looking Statement

This presentation of PolyPid Ltd. (the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses statements relating to our objectives, plans, and strategies, the expected timing of trials, the research, development, and use of our platform technologies, technologies, products and product candidates, potential benefits and advantages of our products and product candidates, and all statements (other than statements of historical facts) that address activities, events, or developments that the Company intends, expects, projects, believes, or anticipates will or may occur in the future, the safety, efficacy and benefits of D-PLEx100 ,the expected timing for NDA submission, FDA acceptance letter and PDUFA date, submission for NTAP reimbursement, EU submission, FDA approval and EU approval and US addressable market. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith.

However, there can be no assurance that management's expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F, filed with the SEC on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

Company Snapshot

PolyPid is an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins.

Core Technology
Kynatrix™ Long-Acting, Controlled-Release Technology

Lead Product
D-PLEX$_{100}$ achieved 60% reduction in SSI in Phase 3 trial

Unique Value
Customizable controlled release, linear delivery of APIs

Next big opportunity
Ultra long GLP-1 Receptor Agonist

Patents
176* granted & pending

Employees
75* employees

HQ
Israel and U.S.

Built for Scale
GMP-certified 18,000 sq ft commercial-ready facility

*As of February 2026

polypid

Introducing The PLEX Platform

Drug molecules are embedded within the alternating polymer-lipid layers



Body moisture activates the platform, triggering controlled surface degradation of the polymer-lipid matrix and constant, linear drug release.



Release is sustained and customizable for days to weeks

PolyPid

The Power of Uncompromising Precision

Zero-Burst Release
No initial drug spike

Customizable Duration
Tunable from several days to several weeks.



Layered Matrix Architecture
Controlled sequential disintegration.

Scalable Manufacturing Process
Designed for consistent quality and commercial-scale production.

Minimal Systemic Exposure
Reduced toxicity and side effects.

Substance Versatility
Suitable for antibiotics, cytotoxic agents, peptides, nucleic acids, and more.

PolyPid

Portfolio Flagship Product: D-PLEX$_{100}$

What is it?
A high-concentration doxycycline formulation (broad-spectrum antibiotic) delivered locally over 30 days.

Prevalence: 15%–25% in abdominal surgery
Colorectal surgery, large incisions, and patients with obesity, diabetes, or immunocompromised have a higher risk of infection.

Indication for Use
Prevention of surgical site infections (SSIs) following abdominal colorectal surgery.

Administration
Applied at the time of surgical closure, with dosing determined by the length of the surgical incision

Regulatory status
Breakthrough Therapy, Fast Track, and QIDP designations, FDA 505(b)(2)

Easily Applied in Any Surgical Setting

Instruction for use:

D-PLEX$_{100}$ applied in abdominal surgery:



The Largest Phase III Trial for Prevention of SSI in Over a Decade

Population
Patients undergoing elective abdominal colorectal surgery with incision length > 20 cm

Primary efficacy endpoint
Reduction in SSI, mortality and reintervention within 30 days post index surgery

Trial size
Global trial US, Europe
ITT cohort: 798 patients

Phenomenal Phase III Clinical Trial Results



A Potential Multi-Million-Dollar Opportunity

12M/Year

US total addressable market in-patient surgical procedures

4.4M/Year

Abdominal Surgeries

Includes colorectal, gyn, urology, and high-risk procedures

**Source IQVIA PM&I Global FlexView. Internal analysis

Out-Licensing Go-To-Market Strategy

Geographic Focus

- U.S. first (largest SSI opportunity)
- ROW: seeking partners in major markets

Revenue Model

- Upfront licensing fees
- Milestones (Development, sales)
- Royalties

Ideal Sales Partners

- Hospital-focused commercial footprint and P&T engagement experience
- Specialty pharma with infection prevention focus
- MedTech manufacturers with strong surgical portfolio (e.g., sutures, surgical implants)

PolyPid

Demonstrated Economic Incentive to Drive Adoption

Direct cost

SSI costs ~$30K/patient[1] on average

- Prolonged length of stay and higher readmission rates
- Re-operation in some cases (to debride and remove infected / necrotic tissues)

Indirect cost

CMS 1-3% penalty on all the yearly Hospital Medicare reimbursement

Reputational cost

Hospital SSI rates are public information and have direct influence on hospital ranking by CMS and U.S. News best hospitals ranking

D-PLEX$_{100}$ is eligible for NTAP program:
up to 75% reimbursement of cost of drug

1. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22.

Surgeons perceive D-PLEX$_{100}$ to be more valuable overall than currently used interventions

How likely are you to prescribe D-PLEX$_{100}$ to prevent SSIs in eligible surgical patients? (% of responders)



Most Mentioned Patients Appropriate for D-PLEX$_{100}$

Patient with a higher risk of infection immunocompromised, comorbidities, obese, uncontrolled diabetics, transplant patients

Patients undergoing Colorectal Surgeries

Any procedure with incisions >10 cm

F/S – On Formulary & Stocked; F/NS = On Formulary, but NOT Stocked; NF/NS = Not on Formulary & Not Stocked

Source: Indegene Market Research October 2025

Pharmacy Directors expect high likelihood of formulary coverage and stocking of D-PLEX$_{100}$

Value perception and **likelihood for formulary coverage** and stocking are high and grow even higher with the introduction of **NTAP**



Innovation Strategy

Our strategy is to leverage the power of our Kynatrix™ delivery platform to elevate treatment effectiveness

Collaborate with R&D partners to:

Improve efficacy

Extend molecule ½ life

Eliminate systemic side effects and toxicity

Key Therapeutic Areas

- Surgical Site Infection
- Metabolic Diseases & Obesity
- Oncology

PolyPid

Innovation Pipeline

Current Pipeline

Therapeutic Araa	Product name	Pre-Clinical	Phase 1	Phase 2	Phase 3	Regulatory Review	In-house / partnership
SSI	D-PLEX$_{100}$						In-house
Metabolic Disease	PP03A						In-house
Oncology	PP04A						IMMUNOGENESIS

Indicated for prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PDUFA date expected early 2027.

Ultra-long GLP-1 receptor agonist released over +50 days in a linear manner overcoming the peak and trough release profile seen in current weekly injection therapy.

Intratumoral delivery of Immunogenesis potent anti-tumor STING agonist combined with PolyPid's delivery technology to enhance treatment for solid tumors.

PolyPid

Manufacturing Excellence Enabling Global Scale

PolyPid operates an 18,000 sq. ft., state-of-the-art GMP facility purpose-built for its proprietary Kynatrix™ drug-delivery technology.

The site enables precise, reproducible production of our proprietary formulations and supports scalable manufacturing from clinical to commercial volumes, ensuring consistent product performance and global supply readiness.




Always Delivering, Our Milestones Too

Expected Timeline

Q1 2026
NDA Submission (US Market)

H2 2026
FDA acceptance letter and PDUFA Target date (eligible for priority review)

H2 2026
Submission for NTAP reimbursement

H2 2026
EU Submission

Q1 2027
FDA approval

H2 2027
EU approval

✓ **Completed**
Phase 3 Global SHIELD II Trial

- Reached primary and all key secondary endpoints
- ~60 global clinical sites

✓ **Completed**
Full CMC & GMP Readiness

State-of-the-art 18,000 sq ft GMP manufacturing facility certified by Israel MoH & EU Qualified Person

✓ **Completed**
Pre-NDA Interactions

In a pre-NDA meeting minutes the FDA agreed that the clinical data package appears adequate to support NDA submission and review. FDA also agreed to a rolling NDA review

polypid

Financials

Stock Information	
Listing	NASDAQ
Ticker	PYPD
52-week range[1]	$2.30-$5.12
Market cap[1]	$100 M
Share Structure	
Shares outstanding	19.0 M
Pre-funded warrants and shares held in abeyance	3.1 M
Warrants	0.8 M @ $3.61 exercise price
Warrants	7.5 M @ $4.50 exercise price
Options outstanding	3.0 M @ $4.8 WAEP

Analyst coverage

CRAIG-HALLUM CAPITAL GROUP LLC

Citizens Bank®

ROTH

HCW H.C.WAINWRIGHT&CO.

1. As of February 6, 2026

Built for Scale and Growth

Large, Attractive Market Opportunity

Addressing a substantial global market of 7M+ surgeries annually, with significant unmet need in surgical site infection prevention.

Multiple Near-Term Catalysts

FDA submission Q1 2026
Expected PDUFA date early 2027

Innovation-Driven Pipeline

A growing pipeline built on PolyPid's differentiated Kynatrix™ platform, enabling expansion into additional high-value indications beyond the lead program.

Thank You!

PolyPid